Drug intelligence / Profile preview

MT-5625

Development stage: Phase 1
Lead developer: Mitsubishi Tanabe Pharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MT-5625 is a plant-based, non-replicating virus-like particle (VLP) vaccine that was under development by Mitsubishi Tanabe Pharma. It is designed as an immunostimulant and has been investigated for use as a rotavirus vaccine. The vaccine is administered intramuscularly and does not contain any live or replicating viral material, instead using VLP technology to stimulate an immune response against rotavirus infection.

Other names: MT 5625MT5625MT-5625

Targets

VP7 (Rotavirus VP7)VP4 (Rotavirus VP4)

Beyond the preview

Go deeper on MT-5625.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-5625.

Explore the full profile